

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 May 2021 (14.05.2021)



(10) International Publication Number
WO 2021/090062 A8

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)
A61K 47/68 (2017.01)

(21) International Application Number:

PCT/IB2020/000917

(22) International Filing Date:

06 November 2020 (06.11.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/932,373 07 November 2019 (07.11.2019) US

(71) Applicant: EISAI R&D MANAGEMENT CO., LTD.
[JP/JP]; 6-10 Koishikawa, 4-chome, Bunkyo-ku, Tokyo,
112-8088 (JP).

(72) Inventors: ALBONE, Earl, F.; 2105 Whitpain Hills, Blue
Bell, PA 19422 (US). SPIDEL, Jared; 100 Wildbrier Road,
Downingtown, PA 19335 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTI-MESOTHELIN ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE




FIG. 13A

(57) Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates such as those comprising eribulin) thereof that bind to mesothelin are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the compositions provided herein.

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

28 April 2022 (28.04.2022)

(15) Information about Correction:

see Notice of 28 April 2022 (28.04.2022)